false 0001815776 0001815776 2022-05-16 2022-05-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2022

 

GRAPHITE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40532

84-4867570

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

Graphite Bio, Inc.

201 Haskins Way, Suite 210

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 484-0886

(Telephone number, including area code, of agent for service)

 

                        

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock

GRPH

The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On May 16, 2022, Graphite Bio, Inc. (the “Company”) issued a press release titled “Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25th Annual Meeting.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release dated May 16, 2022 entitled “Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25th Annual Meeting.”

104

 

Cover Page Interactive Data (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Graphite Bio, Inc.

 

 

 

 

Date: May 16, 2022

 

By:

/s/ Alethia Young

 

 

 

Alethia Young

 

 

 

Chief Financial Officer

 

 

Graphite Bio (NASDAQ:GRPH)
Graphique Historique de l'Action
De Mar 2025 à Avr 2025 Plus de graphiques de la Bourse Graphite Bio
Graphite Bio (NASDAQ:GRPH)
Graphique Historique de l'Action
De Avr 2024 à Avr 2025 Plus de graphiques de la Bourse Graphite Bio